The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
Abstract Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for trea...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Adis, Springer Healthcare
2024-02-01
|
| Saila: | Dermatology and Therapy |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1007/s13555-024-01099-y |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|